Fecal ESBL Resurgence During Antibiotic Treatment

Terminated

• Conditions: Antibiotic Drug Resistance

• Registration Number: NCT03206879
• Lead Sponsor: University Hospital, Akershus

Brief Summary

Norwegian hospitals are struggling to control spread of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) in health care settings. Strict screening and isolation criteria are enforced in hospital, and patients previously infected by ESBL-E are regarded as possible ESBL-E carriers indefinitely. This observational multi-centre cross-sectional study aims to estimate the duration of fecal ESBL-E carriage and to assess the risk of ESBL-E resurgence during hospital stay for patients previously infected by ESBL-E. Through better knowledge of these risk factors, infection control procedures may be better tailored to rhe individual patient.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11
• Study First Submitted: 2017-06-30
• Study First Submitted QC: 2017-06-30
• Study First Posted: 2017-07-02
• Primary Completion: 2018-08
• Study Completion: 2018-12
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-05
• Last Update Posted: 2024-02-06

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Patients with previous infection or colonization with ESBL-E admitted to one of the participating wards. -

Exclusion Criteria

• Not able to give informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
fecal carriage of ESBL-E	Baseline

Secondary Outcome Measures

Name	Time	Method
fecal ESBL-E carriage developed during admission	Baseline (admission)